Central Alerting System
View Alert

Originator: DHSC & NHS England and Improvement: Supply disruption alert

Issue date: 04-Mar-2021 15:10:32

This alert has been issued to:
  • Care Trusts
  • Mental Health Trusts
  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Specialists Trusts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Regional Offices
  • Learning Disabilities Trusts
  • Mental Health & Social Care Trusts
  • Ambulance Trusts
  • Social Care Providers (registered with CAS)
  • Special Health Authorities
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Mental Health & Learning Disabilities Trusts
  • Director of Public Health
  • Acute Trusts
  • Community Trusts
  • GP - Locum
  • NHS 111 and Out of hours providers
  • GP Practices
  • DHSC Supply Disruption - Medicines
  • Community Pharmacy
  • Primary Care Networks
  • GP Practices 1

Action category: Action

Title: Repaglinide 1mg and 2mg tablets - Supply Disruption

Broadcast content:
Generic repaglinide 1mg and 2mg tablets are out of stock until early May 2021.

Limited quantities of repaglinide 500 microgram tablets remain available but are unable to support any increase in demand. 

A limited quantity of Prandin (repaglinide) 500 microgram, 1mg and 2mg tablets remain available but are also unable to support any increase in demand. 

Unlicensed supplies of repaglinide 1mg and 2mg tablets have been sourced. 

Prescribers will need to review all affected patients and assess ongoing need for repaglinide. If ongoing treatment is required, consideration should be given to prescribing an alternative glucose lowering medication where unlicensed imports of repaglinide are not appropriate.

This alert contains further information and action for providers.

Please note that no response is required via the CAS website to this alert.

Additional information: NHS England and NHS Improvement Regional Offices: please cascade this alert to Community Pharmacy.

Alert reference: SDA/2021/005


Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency